Autolus Therapeutics to host Investor Conference Call to discuss AUTO3 data presented at ESMO and to participate in Banking c...
September 08 2020 - 7:00AM
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage
biopharmaceutical company developing next-generation programmed T
cell therapies, today announced that management will host an
investor conference call to discuss AUTO3 data presented at the
European Society for Medical Oncology (ESMO) Virtual Congress 2020
and to participate in Banking conferences through September:
- 9 September 2020 –
The company will participate in an analyst moderated group meeting
at the Wells Fargo Virtual Healthcare
Conference at 9.20 am EDT, 2.20 pm BST and will also host
virtual one-on-one meetings. A live audio webcast of the fireside
chat will be available on the investor relations section of the
Company’s website at Autolus. An archived replay will be available
for a period of 30 days after the conference.
- 15 September 2020
– The company will present at the H.C. Wainwright & Co
22nd Annual Global Investment Conference at 10.30 am EDT,
3.30 pm BST and will also host virtual one-on-one meetings. A live
audio webcast of the presentation will be available on the investor
relations section of the Company’s website at Autolus. An
archived replay will be available for a period of 30 days after the
conference.
- 17 September 2020
– The company will present at the Cantor Fitzgerald Virtual
Global Healthcare Conference at 4.00 pm EDT, 9.00 pm BST
and will also host virtual one-on-one meetings.
- 18 September 2020
– Dr. Christian Itin, chairman and chief executive officer, along
with the AUTO3 clinical team, will host an investor call and
webcast at 8.00 am EDT, 1.00 pm BST to discuss a presentation
related to its AUTO3 program, the company’s CAR T cell therapy
being investigated in the Alexander study, a Phase 1/2 study in
relapsed/ refractory diffuse large B cell lymphoma (DLBCL), during
the ESMO conference. To listen to the webcast and
view the accompanying slide presentation, please go to Autolus.The
call may also be accessed by dialing (866) 652-5200 for U.S. and
Canada callers or (412) 317-6060 for International callers. Please
ask to be joined into the Autolus Therapeutics call. An archived
replay will be available for a period of 12 months after the
call.
- 22 September 2020
– The company will participate in a Q&A at the virtual
JP Morgan CEO Series Investor Call at 11.00 am
EDT, 4.00 pm BST.
About Autolus Therapeutics
plc
Autolus is a clinical-stage biopharmaceutical
company developing next-generation, programmed T cell therapies for
the treatment of cancer. Using a broad suite of proprietary and
modular T cell programming technologies, the company is engineering
precisely targeted, controlled and highly active T cell therapies
that are designed to better recognize cancer cells, break down
their defense mechanisms and eliminate these cells. Autolus has a
pipeline of product candidates in development for the treatment of
hematological malignancies and solid tumors. For more information
please visit www.autolus.com.
Contact:
Lucinda Crabtree, PhDVice President, Investor
Relations and Corporate Communications+44 (0) 7587 372
619l.crabtree@autolus.com
Julia Wilson+44 (0) 7818
430877j.wilson@autolus.com
Susan A. NoonanS.A. Noonan
Communications+1-212-966-3650susan@sanoonan.com
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Apr 2023 to Apr 2024